DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Micronized Glyburide (Glyburide) - Published Studies


Published Studies Related to Micronized Glyburide

Well-designed clinical trials related to Micronized Glyburide

Glyburide is associated with attenuated vasogenic edema in stroke patients. [2014]

Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects. [2011.07]

Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. [2011.05]

Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT. [2011.05]

Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia. [2011.05]

Effect of repaglinide versus glyburide on postprandial glucose and insulin values in elderly patients with type 2 diabetes. [2011.01]

Effect of the bile acid sequestrant colesevelam on the pharmacokinetics of pioglitazone, repaglinide, estrogen estradiol, norethindrone, levothyroxine, and glyburide. [2010.05]

Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. [2010.01]

Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. [2010.01]

Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). [2010.01]

Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. [2010]

Can pregnant diabetics be treated with glyburide? [2009.11]

Impact of rosiglitazone and glyburide on nitrosative stress and myocardial blood flow regulation in type 2 diabetes mellitus. [2009.07]

Neonatal adiposity following maternal treatment of gestational diabetes with glyburide compared with insulin. [2009.05]

Coadministration of muraglitazar plus glyburide: improvement of glycaemic and lipid profiles in patients with type 2 diabetes. [2009.04]

Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes. [2008.07]

Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. [2007.11]

Glyburide for the treatment of gestational diabetes. A critical appraisal. [2007.07]

Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study. [2007.05]

A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events: A comparison of glyburide with other secretagogues and with insulin. [2007.02]

Bioequivalence of two oral formulations of glyburide (glibenclamide). [2007]

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [2006.12.07]

Effects of glimepiride and glyburide on glucose counterregulation and recovery from hypoglycemia. [2006.01]

Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study. [2005.10]

Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study. [2005.09]

PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. [2005.09]

Well-designed clinical trials possibly related to Micronized Glyburide

Effects of Juglans regia L. leaf extract on hyperglycemia and lipid profiles in type two diabetic patients: a randomized double-blind, placebo-controlled clinical trial. [2014]

Anti-hyperglycemic and anti-hypercholesterolemic effects of Aloe vera leaf gel in hyperlipidemic type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. [2012]

Attitudes and practices of healthcare providers regarding gestational diabetes: results of a survey conducted at the 2010 meeting of the International Association of Diabetes in Pregnancy Study Group (IADPSG). [2011.08]

Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes. [2011.07]

Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. [2011.06]

Sesame oil exhibits synergistic effect with anti-diabetic medication in patients with type 2 diabetes mellitus. [2011.06]

Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. [2011.04]

Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes. [2011]

Effects of insulin versus sulphonylurea on beta-cell secretion in recently diagnosed type 2 diabetes patients: a 6-year follow-up study. [2010.09]

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. [2010.05]

Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. [2010.05]

Exenatide versus glibenclamide in patients with diabetes. [2010.03]

Momordica charantia for type 2 diabetes mellitus. [2010.02.17]

Psychometric evaluation of the Diabetes Symptom Checklist-Revised (DSC-R)--a measure of symptom distress. [2009.11]

Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. [2009.11]

Effect of two starting insulin regimens in patients with type II diabetes not controlled on a combination of oral antihyperglycemic medications. [2009.05]

Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study. [2009.03]

Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. [2009.02]

Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review. [2009.01]

Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. [2009]

A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol. [2008.10]

The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia. [2008.06]

Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. [2008.05]

Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone. [2008.05]

Treating the mother - protecting the unborn: The safety of hypoglycemic drugs in pregnancy. [2008.03]

Glibenclamide dose response in patients with septic shock: effects on norepinephrine requirements, cardiopulmonary performance, and global oxygen transport. [2007.11]

The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. [2007.11]

Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes. [2007.09]

Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. [2007.09]

Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes. [2007.08]

Simultaneous assay of metformin and glibenclamide in human plasma based on extraction-less sample preparation procedure and LC/(APCI)MS. [2007.07.01]

Oral antidiabetic agents in pregnancy and lactation: a paradigm shift? [2007.07]

Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. [2007.06]

[Glibenclamide in the treatment for gestational diabetes mellitus in a compared study to insulin] [2007.06]

Oral Antidiabetic Agents in Pregnancy and Lactation: A Paradigm Shift? (July/August). [2007.05.29]

Pioglitazone has anti-inflammatory effects in patients with Type 2 diabetes. [2007.04]

A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. [2007.01]

[ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?] [2007.01]

Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. [2007]

A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. [2006.12]

Insulins and oral hypoglycemic agents in pregnancy. [2006.11]

Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. [2006.10]

Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. [2006.10]

Gliclazide treatment lowers serum ICAM-1 levels in poorly controlled type 2 diabetic patients. [2006.09]

The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients. [2006.09]

Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria. [2006.09]

Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes. [2006.08]

An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin. [2006.08]

Beta-cell response to metformin-glibenclamide combination tablets (Glucovance) in patients with type 2 diabetes. [2006.07]

Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia. [2006.06]

Comparison of the antioxidant and vascular effects of gliclazide and glibenclamide in Type 2 diabetic patients: a randomized crossover study. [2006.05]

Randomized, double-blind, placebo-controlled crossover pilot study of a potassium channel blocker in patients with septic shock. [2006.04]

Effect of the oral hypoglycaemic sulphonylurea glibenclamide, a blocker of ATP-sensitive potassium channels, on walking distance in patients with intermittent claudication. [2006.03]

Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. [2006.03]

Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. [2006.02]

The efficacy of folk medicines in the management of type 2 diabetes mellitus: results of a randomized controlled trial of Syzygium cumini (L.) Skeels. [2006.02]

Improving metabolic control leads to better working memory in adults with type 2 diabetes. [2006.02]

Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3. [2006.02]

Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide. [2006.02]

Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes. [2006.01]

Impact of rosiglitazone on glycaemic control, insulin levels and blood pressure values in patients with type 2 diabetes. [2006]

Effects of pharmacological modulation of the ATP-sensitive potassium channels on the development of warm-up angina pectoris. [2006]

Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial. [2005.12.06]

The impact of the timing of Humalog Mix25 injections on blood glucose fluctuations in the postprandial period in elderly patients with type 2 diabetes. [2005.12]

The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). [2005.11]

Enhancement of blood glucose lowering effect of a sulfonylurea when coadministered with an ACE inhibitor: results of a glucose-clamp study. [2005.09]

Effect of ischaemic preconditioning on regional release of inflammatory markers. [2005.09]

Efficacy of glimepiride in Japanese type 2 diabetic subjects. [2005.06]

Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide. [2005.05]

Electronic pill-boxes in the evaluation of oral hypoglycemic agent compliance. [2005.04]

Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. [2005.02.15]

Repaglinide administration improves brachial reactivity in type 2 diabetic patients. [2005.02]

Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients. [2005.01]

Perinatal outcomes and the use of oral hypoglycemic agents. [2005]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017